What went well
- The July 2025 public offering landed on the balance sheet: cash and cash equivalents jumped to EUR 589.7 million at September 30, 2025 (from EUR 144.2 million at year-end 2024), driven by EUR 608.1 million of net proceeds, supporting a cash runway into Q4 2027.
- Abivax became essentially debt-free during the period, with Heights Capital Management fully converting its notes to equity and the Kreos/Claret structured debt being converted/redeemed (the company notified bondholders on November 28, 2025 of intent to prepay Tranches B and C in full before year-end).
- Obefazimod's ABTECT data was showcased at major venues: late-breaking presentations of the 8-week induction results (including updated safety data and prior-advanced-therapy subgroup analyses) at the 2025 United European Gastroenterology (UEG) meeting, plus patient-reported-outcomes data (November 3, 2025) showing significant quality-of-life improvements.
- Shareholders' equity swung strongly positive to EUR 511.2 million (from EUR 40.6 million), and total assets reached EUR 652.1 million.
What went wrong
- Reported losses ballooned on non-cash items tied to the surging share price: nine-month net loss widened to EUR 254.1 million (from EUR 136.9 million), including a EUR 79.7 million net financial loss.
- The financial loss was driven by EUR 36.0 million and EUR 29.9 million fair-value increases on the Heights convertible notes and Kreos/Claret warrants respectively (as the stock rose before conversion), EUR 15.1 million of non-cash royalty-certificate revaluation, and EUR 9.1 million of non-cash FX losses on USD-denominated cash.
- Operating loss increased EUR 44.2 million to EUR 174.4 million, with R&D up EUR 25.4 million to EUR 133.4 million (UC Phase 3, Crohn's Phase 2b, other obefazimod studies, and CMC/supply-chain build-out).
- G&A rose EUR 16.5 million to EUR 41.8 million, almost entirely from EUR 15.1 million of employer taxes and social contributions on French free-share (AGA) awards triggered by the higher share price - a direct cost of the stock's re-rating.
- Operating income declined EUR 4.0 million to EUR 4.1 million year over year.
Guidance Changes
| Metric | Period | Current guidance |
|---|---|---|
| Cash runway | as of Q3 2025 report | Reaffirmed into the fourth quarter of 2027 (cash of EUR 589.7M at Sep 30, 2025) |
| ABTECT Phase 3 maintenance topline | upcoming | On track for Q2 2026 |
| Debt | by year-end 2025 | Intention to prepay Kreos/Claret Tranches B and C in full before December 31, 2025 (no remaining structured debt) |
Performance Breakdown
| Metric | YoY | Note |
|---|---|---|
| Cash and cash equivalents | EUR 589.7M at Sep 30, 2025 | Up EUR 445.5M from year-end 2024 on July 2025 offering net proceeds; partly offset by EUR 137.9M operating use and EUR 23.4M debt service. |
| R&D costs (9M) | EUR 133.4M (+EUR 25.4M) | UC Phase 3 (+EUR 8.6M), Crohn's Phase 2b (+EUR 5.4M), other obefazimod studies (+EUR 6.0M), CMC/supply chain (+EUR 5.9M). |
| G&A costs (9M) | EUR 41.8M (+EUR 16.5M) | EUR 15.1M of employer tax/social contributions on AGAs from the higher share price, plus EUR 1.2M higher professional fees. |
| Operating loss (9M) | EUR 174.4M (+EUR 44.2M) | Higher R&D and G&A. |
| Net financial loss (9M) | EUR 79.7M (vs EUR 6.7M) | Largely non-cash: fair-value increases on Heights notes and Kreos/Claret warrants, royalty-certificate revaluation and FX. |
| Net loss (9M) | EUR 254.1M (vs EUR 136.9M) | Wider operating loss plus large non-cash financial charges. |
Earnings Call Themes & Trends
| Topic | Previous mention | Current period | Trend |
|---|---|---|---|
| Share-price-driven non-cash charges | - | The stock's re-rating after positive Phase 3 induction data drove large non-cash fair-value and employer-social-charge expenses (Heights EUR 36.0M, Kreos/Claret EUR 29.9M, EUR 15.1M AGA charges), inflating reported losses. | — |
| Deleveraging | Structured debt outstanding | Heights notes fully converted; Kreos/Claret Tranche A converted and Tranches B/C to be prepaid by year-end 2025. | — |
| Clinical data dissemination | Topline reported July 2025 | Late-breaking UEG presentations plus patient-reported-outcome data reinforced the obefazimod induction profile. | — |
More on Abivax S.A.
See how Top Bucket AI works for your firm
Request DemoTop Bucket AI Research
Stay ahead of private markets
Research and market intelligence for private-markets professionals.
✓
You're subscribed.
Thanks for signing up.